Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03109977 · ClinicalTrials.gov registry record · Phase 1
Imaging With a New Agent That Finds a Cancer Protein Called HER2
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03109977: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03109977 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03109977, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to test if an imaging agent called Zr-DFO-pertuzumab that finds HER2 proteins can be used to take pictures of HER2-positive cancer.
Interventions
- DRUG Zr-DFO-pertuzumab PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-03-31 |
| Est. Completion | 2018-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03109977
The ClinicalTrials.gov registry entry for NCT03109977 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zr-DFO-pertuzumab PET/CT is the first listed.
NCT03109977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03109977 about?
NCT03109977 is a clinical study titled "Imaging With a New Agent That Finds a Cancer Protein Called HER2". The purpose of this study is to test if an imaging agent called Zr-DFO-pertuzumab that finds HER2 proteins can be used to take pictures of HER2-positive cancer.
What is the current status of trial NCT03109977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-03-31. Estimated completion is 2018-04-12.
What interventions are being tested in trial NCT03109977?
The interventions under investigation include: Zr-DFO-pertuzumab PET/CT (DRUG).
Who is sponsoring clinical trial NCT03109977?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.